Minnesotans with high blood pressure may be eligible to take part in a Fairview research study exploring the role genetics can play in finding the best treatment options for patients with high blood pressure.
“We believe we can dramatically cut the time, cost and side effects involved in managing high blood pressure through the use of gene-specific treatment protocols,” Fairvew Medical Group vice president of medical practice Dr. Dang Tran said in a press release.broadstreet.zone(48036);
To conduct the study, Fairview is partnering with Geneticure, a Minnesota-based pharmacogenomics testing company. Early research indicates Geneticure’s patented genetic test can help clinicians personalize hypertension treatment which may result in faster, better care.
All study participants will be asked to complete up to eight clinic visits over the course of 12 months, the cost of which would be covered by the study. Participants will only be responsible for the costs of prescribed medication and any lab tests
Skip to content
News and other stories about real people, places, and events in Forest Lake and nearby suburbs.